Dermira, Inc. (DERM): Price and Financial Metrics
GET POWR RATINGS... FREE!
DERM Stock Summary
- With a one year PEG ratio of 0.47, JOURNEY MEDICAL CORP is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
- JOURNEY MEDICAL CORP's stock had its IPO on November 12, 2021, making it an older stock than just 0.53% of US equities in our set.
- JOURNEY MEDICAL CORP's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -135.63%, greater than the shareholder yield of merely 4.2% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to JOURNEY MEDICAL CORP are BLBX, LPRO, TELA, XERS, and PWFL.
- To check out JOURNEY MEDICAL CORP's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001867066.
DERM Valuation Summary
- DERM's EV/EBIT ratio is -1.2; this is 112.12% lower than that of the median Healthcare stock.
- Over the past 14 months, DERM's price/sales ratio has gone down 2.9.
Below are key valuation metrics over time for DERM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DERM | 2023-01-20 | 0.5 | 1.6 | -1.0 | -1.2 |
| DERM | 2023-01-19 | 0.6 | 1.7 | -1.1 | -1.3 |
| DERM | 2023-01-18 | 0.6 | 1.6 | -1.1 | -1.3 |
| DERM | 2023-01-17 | 0.6 | 1.7 | -1.1 | -1.3 |
| DERM | 2023-01-13 | 0.6 | 1.7 | -1.1 | -1.3 |
| DERM | 2023-01-12 | 0.6 | 1.7 | -1.1 | -1.3 |
DERM Stock Price Chart Interactive Chart >
DERM Price/Volume Stats
| Current price | $2.29 | 52-week high | $5.95 |
| Prev. close | $1.98 | 52-week low | $1.05 |
| Day low | $1.99 | Volume | 40,392 |
| Day high | $2.34 | Avg. volume | 47,379 |
| 50-day MA | $1.79 | Dividend yield | N/A |
| 200-day MA | $2.94 | Market Cap | 40.54M |
Dermira, Inc. (DERM) Company Bio
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. The company was founded in 2010 and is based in Menlo Park, California.
Latest DERM News From Around the Web
Below are the latest news stories about JOURNEY MEDICAL CORP that investors may wish to consider to help them evaluate DERM as an investment opportunity.
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial OfficerSCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another |
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular RosaceaTopline data expected in the first half of 2023SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of D |
Journey Medical Touts Positive PK Data For Bacterial Infection CandidateJourney Medical Corporation (NASDAQ: DERM) announced PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 study of DFD-29 for papulopustular rosacea in collaboration with Dr. Reddy's Laboratories Ltd (NYSE: RDY). Papulopustular rosacea is associated with "whitehead" pustules, pus-filled blemishes, and red, swollen bumps. The PK study was designed as a comparative bioavailability study of DFD-29 (Minocycline Modified Release Capsules 40 mg) versus Solodyn (Minoc |
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29Phase 3, registrational studies remain on track for first half of 2023 topline data readoutSCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced positive PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 clinical s |
Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic ConferenceSCOTTSDALE, Ariz., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical’s management team will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on |
DERM Price Returns
| 1-mo | 19.27% |
| 3-mo | 3.15% |
| 6-mo | -42.75% |
| 1-year | -57.12% |
| 3-year | -87.92% |
| 5-year | -91.93% |
| YTD | 19.27% |
| 2022 | -64.31% |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 110.85% |
| 2018 | -74.15% |
Continue Researching DERM
Want to do more research on NA's stock and its price? Try the links below:NA (DERM) Stock Price | Nasdaq
NA (DERM) Stock Quote, History and News - Yahoo Finance
NA (DERM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...